Retro Biosciences, the longevity startup backed by OpenAI CEO Sam Altman, has raised more money at a $1.8 billion valuation, ...

Biogen and Denali Therapeutics said a closely watched experimental therapy for Parkinson’s disease failed to slow the ...

My patients are replacing olive oil with beef tallow, even if they don't tell me during cardiac rehab,” writes a clinical ...

The company behind the analytics, Vizient, touts MGH's increasing hospice enrollment to improved mortality performance.

A type of targeted chemotherapy developed by China-based Kelun-Biotech and licensed to Merck cut the risk of tumor ...

Jeffery Taubenberger, the acting head of the NIAID, the NIH’s infectious disease institute, is reported to have stepped down.

Watch as NIH Director Jay Bhattacharya is questioned by the Senate Appropriations Committee this morning on President Trump’s ...

Eli Lilly reported that in a late-stage trial, its next-generation obesity drug led to weight loss approaching the ...

On this week’s episode of “The Readout LOUD,” the hosts discuss STAT's Breakthrough Summit West, where powerful leaders from ...

Peter Haytaian, a former top executive at health insurance company Elevance Health, will have to sit for a deposition in the ...

A next-gen Eli Lilly obesity drug led to bariatric-surgery levels of weight loss in a study, but also saw patients dropping ...

Besides showing skepticism on the budget, senators grilled the NIH director about a leadership vacuum, two viral outbreaks, and the pace of funding.